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Anaphylaxis Following Foam Sclerotherapy: A Life Threatening
Complication of Non Invasive Treatment For Varicose Veins*
J.R.H. Scurr,* R.K. Fisher, S.B. Wallace and G.L. Gilling-Smith
Regional Vascular Unit, Royal Liverpool University Hospital, UK
We report an anaphylactic reaction following ultrasound guided foam sclerotherapy (UGFS) to lower limb varicosities. A
tortuous anterolateral thigh vein of a 62 year-old woman was unsuccessfully ablated with UGFS. A further session of
UGFS, 6 months later, resulted in a non-fatal anaphylactic reaction that required resuscitation with adrenaline. The patient
was not known to be allergic to the sclerosant used and had not suffered any adverse effects after her initial treatment. This
case demonstrates the possibility of anaphylaxis following UGFS. Those performing sclerotherapy require appropriate
resuscitation equipment and training.
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Sclerotherapy is not a new treatment for varicose
veins.1 The use of ultrasound guidance and the intra-
venous injection of sclerosants as foam, rather than
liquid, has re-established sclerotherapy (ultrasound
guided foam sclerotherapy, UGFS) as an alternative to
surgery for the treatment of varicose veins.2,3
Anaphylaxis is a rare but recognized complication
of liquid sclerotherapy4 and the manufacturers of
sclerosants advise that sclerotherapy should not be
performed unless adequate resuscitation equipment
is available.5 We report anaphylaxis following foam
sclerotherapy in order to alert specialists to the possi-
bility of this life threatening complication. We also
consider the implications of this complication and
review guidelines for management (Fig. 1).
Case Report
A62year-oldwomanwith a large tortuous anterolateral
thigh vein (basic CEAP classification C2,S,EP,As,Pr)
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previous venous surgery or sclerotherapy. She was
obese (BMI >35) and had angina, hypertension and
mild asthma with hay fever. She described allergies
to pollen and perfume, but to no conventional
medications.
UGFS was considered to be preferable to conven-
tional surgery and was performed in a dedicated
ambulatory day surgery unit assisted by a vascular
technologist. Cannulation of the vein was performed
under ultrasound guidance without local anaesthesia.
A total of 4 mL of 3% purified sodium tetradecyl
sulphate (STD - Fibrovein, STD Pharmaceuticals
Ltd, Hereford, UK) was administered as foam (The
Tessari method, Sclerosant:Air¼ 1:3).1 A compression
bandage was applied and the patient observed in a
recovery area before discharge.
Six month clinical and duplex follow up identified
persistent patency and incompetence of the treated
vein for which she agreed to further treatment. This
involved further canulation of the vein, again without
local anesthesia. A total of 12 mL (3 mL, 1% STD) of
foam was injected under ultrasound guidance and
the leg placed in compression.
Within 20 minuets of this procedure, whilst in the
recovery area, the patient reported her tongue and
lips as feeling ‘‘hot’’. She was observed to have facialer CC BY-NC-ND license.
88 J. R. H. Scurr et al.flushing and at this stage 10 mg of IV Chlorphenamine
was administered. Rapidly her tongue and lips started
to swell and her breathing became wheezy. She deve-
loped a tachycardia (120 beats/minute) and became
hypotensive (79/50 mmHg).EJVES Extra Vol 13, June 2007Her resuscitation was co-ordinated by an anaes-
thetist who administered high flow oxygen and Ad-
renaline (epinephrine) [1:1000 solution 0.5 mL (500
micrograms) intramuscularly]. Intravenous fluids and
Hydrocortisone (100 mg) were also administered.Stridor, wheeze,
respiratory distress or
clinical signs of shock1
Repeat in 5 minutes if no clinical
improvement
Antihistamine (chlorphenamine)
10-20 mg IM/or slow IV
If clinical manifestations of shock
do not respond to drug treatment
give 1-2 litres IV fluid.4
Rapid infusion or one repeat dose
may be necessary 
IN ADDITION
Consider when compatible history of severe allergic-type
reaction with respiratory difficulty and/or hypotension
especially if skin changes present
Oxygen treatment
when available
Adrenaline (epinephrine)2,3
1:1000 solution
0.5 mL (500 micrograms) IM
For all severe or recurrent
reactions and patients
with asthma give
Hydrocortisone
100-500 mg IM/or slowly IV  
1. An inhaled beta2-agonist such as salbutamol may be used as an adjunctive measure 
if bronchospasm is severe and does not respond rapidly to other treatment. 
2. If profound shock judged immediately life threatening give CPR/ALS if necessary. Consider 
slow IV adrenaline (epinephrine) 1:10,000 solution.  This is hazardous and is recommended 
only for an experienced practitioner who can also obtain IV access without delay. 
Note the different strength of adrenaline (epinephrine) that may be required for IV use. 
3. If adults are treated with an adrenaline auto-injector, the 300 micrograms will usually be sufficient.   
A second dose may be required. Half doses of adrenaline (epinephrine) may be safer for patients on  
amitriptyline, imipramine, or beta blocker. 
4. A crystalloid may be safer than a colloid. 
Fig. 1. Algorithm for the management of anaphylaxis in adults by first medical responders (reproduced with permission of
Resuscitation Council UK).
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tubation, her recovery was monitored on a critical care
unit overnight. Shewasdischargedhomeafter 24 hours
of uneventful observation.
Discussion
Although anaphylaxis has been reported following
liquid sclerotherapy to lower limb varicosities, a recent
systematic review identified no reported cases of ana-
phylaxis following UGFS.6 Nonetheless, practitioners
should be aware that exposure to sclerosant in either
liquid or foam form can precipitate an allergic reaction
particularly in atopic individuals and/or those pre-
viously exposed to sclerosants.
Local anaesthesia may also be responsible for the
development of adverse reactions either as an allergic
reaction or from systemic side effects. In this case how-
ever, the patient had not received local anaesthetic as
part of her UGFS treatment and anaphylaxis was
attributed solely to repeated exposure to sclerosant.
Although rare, anaphylaxis after sclerotherapy is
potentially life threatening. Nonetheless, a survey of
the Vascular Surgical Society in 1998 found that only
five percent of members discussed with their patients
the possibility of an allergic reaction to sclerotherapy
and only 17 percent obtained written consent for the
procedure.7 Against a background of increasing litiga-
tion against practitioners, failure to obtain fully
informed written consent may be unwise.Foam sclerotherapy is generally considered a low
risk procedure and it is often performed in an out-
patient ‘office’ setting with early ambulation and dis-
charge of the patient. While this may be acceptable in
most cases, practitioners should ensure that they are
trained in resuscitation techniques and that appropri-
ate resuscitation equipment is available.
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